Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329433 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00329433 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 120 participants.
The verdict
NCT00329433, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
A blood clot in the veins, also known as deep venous thrombosis (DVT), is one of the most common complications after surgery. This may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary embolism (PE). After heart surgery the incidence of DVT ranges from 20-48% and following lung surgery the incidence is 19-26%. In order to decrease the likelihood of this complication, patients receive by injection a blood thinning medicine. Heparin is the usual medicine used for this purpose following heart and lung surgery. Recently there have been reports that other medicines may be more effective than heparin for this purpose. Also there have been reports that some patients develop antibodies to heparin. When this occurs, this may prevent the heparin from being effective and may even promote the formation of blood clots. Antibodies to heparin may be present more often following heart and lung surgery than other types of surgery. There is a new medicine called desirudin (Iprivask), which may be used instead of heparin to prevent blood clots following heart and lung surgery. Desirudin is currently approved by the FDA to prevent blood clots following hip surgery. The purpose of this study is to compare desirudin with heparin for the prevention of vein clots after heart and lung surgery.
Interventions
- DRUG Heparin
- DRUG Desirudin (Iprivask™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329433
The ClinicalTrials.gov registry entry for NCT00329433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.
NCT00329433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329433 about?
NCT00329433 is a clinical study titled "Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery". A blood clot in the veins, also known as deep venous thrombosis (DVT), is one of the most common complications after surgery. This may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary embolism (PE). After heart surgery the incidence of DVT ranges from 20...
What is the current status of trial NCT00329433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00329433?
The interventions under investigation include: Heparin (DRUG), Desirudin (Iprivask™) (DRUG).
Who is sponsoring clinical trial NCT00329433?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.